J. Budman

发表

Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding.

M. Yaffe, S. Smerdon, S. Volinia, 1999, Molecular cell.

Induced fit activation mechanism of the exceptionally specific serine protease, complement factor D.

A. Whitty, S. Bixler, J. Budman, 1999, Biochemistry.

Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat

J. Budman, U. Klein, Cécile Yu, 2011, Journal of cardiovascular pharmacology.

Assays for nonhomologous end joining in extracts.

G. Chu, J. Budman, 2006, Methods in enzymology.

Processing of DNA for nonhomologous end‐joining by cell‐free extract

Gilbert Chu, G. Chu, J. Budman, 2005, The EMBO journal.

Processing of DNA for Nonhomologous End-joining Is Controlled by Kinase Activity and XRCC4/Ligase IV*

G. Chu, J. Budman, Sunny A Kim, 2007, Journal of Biological Chemistry.

P0898 : TD-6450, A next generation once-daily NS5A inhibitor, has potent antiviral activity following a 3-day monotherapy study in genotype 1 HCV infection

J. Budman, E. Lawitz, C. Washington, 2015 .

Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI).

J. Budman, S. Choi, R. M. Mckinnell, 2018, ACS medicinal chemistry letters.

Abstracts Accepted for American Conference on Pharmacometrics 2015 (ACoP6)

P. Worboys, J. Budman, Uyen, 2015, Journal of Pharmacokinetics and Pharmacodynamics.